As of Tuesday’s market close, shares of Skye Bioscience, Inc. (NASDAQ: SKYE) had jumped 18.81% to $3.41, driven by a slew of positive developments on its main anti-obesity candidate, nimacimab. The company’s involvement in important scientific and investor gatherings, such as the American Diabetes Association’s (ADA) 85th Scientific Sessions, which took place in Chicago from June 20–23, 2025, was the catalyst for the upward momentum.
Showcasing Progress Through a Dedicated Video Series
In order to address unmet requirements in the treatment of obesity, Skye Bioscience published its “Anatomy of Progress” video series, a four-part update that focuses on the ongoing development of nimacimab, a new peripherally restricted CB1 receptor antibody. The business emphasized the possible benefits of focusing on peripheral CB1 receptors while lowering the neurological dangers that small molecule CB1 inhibitors usually entail.
CEO Punit Dhillon emphasized nimacimab’s mechanistic distinction, noting its ability to bypass the brain while offering meaningful therapeutic outcomes for weight loss. This approach could position nimacimab as a safer alternative to earlier CB1 inhibitors that were hampered by adverse neuropsychiatric side effects.
Scientific Insights Shared at Major Obesity Symposiums
Skye’s management team participated in a non-incretin therapeutics panel at an investor-focused obesity event hosted by Evercore. Moderated by analysts Liisa Bayko and Umer Raffat, the discussion included respected obesity experts Dr. Helena Rodbard and Dr. Sean Wharton, who reviewed nimacimab’s unique clinical profile and its role in expanding the non-incretin therapeutic toolkit.
Key preclinical findings demonstrating nimacimab’s capacity to promote weight reduction, lessen inflammation caused by obesity, and enhance liver function without penetrating the central nervous system were presented by Skye’s CSO, Dr. Chris Twitty, at the ADA symposium. According to these results, nimacimab can be used as a stand-alone treatment or in conjunction with GLP-1 therapy.
Positioning for Market Expansion
The company also discussed the market potential of nimacimab in its “Market Opportunity” presentation, supported by insights from physicians who recognized the need for innovative non-GLP-1 treatments. Skye Bioscience’s strategic direction signals a significant step forward in redefining obesity care through a targeted, peripheral CB1-blocking antibody platform.
